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Abstract
Plasmacytoid dendritic cells (pDCs) are a subset of DCs whose major function relies on their capacity to produce large
amount of type I IFN upon stimulation via TLR 7 and 9. This function is evolutionary conserved and place pDC in critical
position in the innate immune response to virus. Here we show that rat pDC constitutively express TNF-related activation-
induced cytokine (TRANCE) also known as Receptor-activating NF-kB ligand (RANKL). TRANCE/RANKL is a member of the
TNF superfamily which plays a central role in osteoclastogenesis through its interaction with its receptor RANK. TRANCE/
RANK interaction are also involved in lymphoid organogenesis as well as T cell/DC cross talk. Unlike conventional DC, rat
CD4high pDC were shown to constitutively express TRANCE/RANKL both at the mRNA and the surface protein level. TRANCE/
RANKL was also induced on the CD4low subsets of pDC following activation by CpG. The secreted form of TRANCE/RANKL
was also produced by rat pDC. Of note, levels of mRNA, surface and secreted TRANCE/RANKL expression were similar to that
observed for activated T cells. TRANCE/RANKL expression was found on pDC in all lymphoid organs as well blood and BM
with a maximum expression in mesenteric lymph nodes. Despite this TRANCE/RANKL expression, we were unable to
demonstrate in vitro osteoclastogenesis activity for rat pDC. Taken together, these data identifies pDC as novel source of
TRANCE/RANKL in the immune system.
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Introduction
Dendritic cells (DC), as antigen presenting cells (APC), play a
key role in the induction of adaptive immunity [1]. Several DC
subsets with specific phenotype and function have been described
in human and mouse model [2,3]. The two main DC populations
described are conventional DC (cDC) and plasmacytoid DC
(pDC). pDC have been first described as plasmacytoid monocytes
and plasmacytoid T cells [4]). They were finally described as DC
in the 1990s [5], and were shown to be the natural IFN-producing
cells [6]. Indeed, pDC produce enormous amounts of type 1
interferon (IFN) upon virus recognition [7] which is mediated by
TLR7 and 9, two TLR strongly expressed in pDC [8]. pDC
subsets with different phenotype and function have been recently
described. In human, CD2+ and CD22 pDC have been described
with CD2+ pDC exhibiting an in vitro cytotoxic activity and
expression of lysozyme [9]. CD123high and low pDC have also been
described in patients with multiple sclerosis in which the
predominance of one or the other subset is correlated with the
gravity of the disease [10]. In mouse, CD4+ and CD42 pDC have
been identified with CD42 pDC being the major source pDC
subset that migrate into lymph nodes in response to infection [11].
A subset of CCR9+ pDC was recently shown to exhibit tolerogenic
functions [12].
TRANCE is a member of the TNF superfamily, also called
receptor activator of NF-kB ligand (RANKL), osteoprotegerin
ligand (OPGL), osteoclast differentiation factor (ODF), TNFSF11
and CD254 [13]. TRANCE binds to the receptor activator of NF-
kB (RANK) also known as TRANCE-receptor, and to the decoy
receptor osteoprotegerin (OPG). TRANCE is expressed mainly on
osteoblasts and stromal [14,15] inducing maturation and activa-
tion of osteoclast (OC) precursor in fully functional OC able to
degrade bone matrix. Stromal cells, activated T and B cells were
also shown to express TRANCE [16,17,18]. Besides playing key
role in osteoclastogenesis [13], TRANCE-RANK interaction
promotes mature DCs survival and cytokine secretion in DC
[17]. In vivo, TRANCE-RANK interaction was shown to play an
important role in CD40L-independant CD4+ T cell response to
virus [19] and to be required for lymph node organogenesis [20].
Indeed, mice deficient for TRANCE gene lacks all the lymph
nodes. They also exhibit severe osteopetrosis, a consequence of
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their lack of osteoclasts. In fact, TRANCE plays a key role in
linking bone physiology and immune system.
We report, herein, that rat pDC constitutively expressed
TRANCE mRNA and confirmed the expression of both
membrane and soluble form of the protein.
Results and Discussion
Constitutive TRANCE mRNA expression by rat pDC
We previously described three DC subsets in rat spleen [21].
Conventional DCs (cDCs) expressed CD103 (clone OX62) and
can be separated into CD4+SIRPa+ and CD42 SIRPa2 cDCs
[22]. We described rat plasmacytoid DC as CD1032 CD11b2
CD45+ and CD4high cells [23]. We sought to identify genes
specifically expressed in these spleen DC subsets and global gene
expression was thus assessed in freshly extracted as well as TLR9-
stimulated CD4+ and CD42 cDC, and pDC using rat specific
gene arrays. Among the genes specifically expressed in resting
pDC, we identified TRANCE. We confirmed these data using real
time QPCR (Fig. 1A) and observed that the level of TRANCE
mRNA expression in resting pDC was similar to that observed at
the peak of expression in activated T cells which are known to
strongly expressed TRANCE [24]. In addition, TRANCE mRNA
was not expressed in CD4+ and CD42 cDCs, at the resting state.
Using a newly generated monoclonal antibody against rat pDC
(clone 85C7), we recently identified two pDC subsets based on the
expression of CD4 (Fig. 1B, left dot-plots) (Anjubault et al,
unpublished results), as recently shown in mice [11]. In the spleen,
the majority of pDC expressed high levels of CD4 [23], with
CD4low pDC representing 10–20% of total 85C7+ cells (Fig. 1B).
After sorting of CD4high and CD4low cells, we observed that both
of these subsets share features of pDC usually described (same
morphology, expression of TLR7 and 9, type I IFN production)
and expressed similarly siglec-H (Fig. 1B, right histograms) a pDC
specific marker identified in mice [25]. However, as shown in
figure 1C, TRANCE expression appeared to be differentially
regulated in these subsets. A high level of TRANCE mRNA
expression by resting CD4high pDC was confirmed and this
expression was rapidly down-regulated after type B CpG-induced
maturation. Similar results were obtained after stimulation by
CD40L or influenza (data not shown). Type A CpG appeared to
maintain TRANCE expression during the first 6 hours but
induced a dramatic down regulation at 24 h. In CD4low pDC, a
very low level of TRANCE mRNA was detected at resting state
(Fig. 1C) but TLR9 stimulation induced a strong upregulation of
TRANCE at 6 h followed by a down regulation at 24 h. At 6 h,
the levels of TRANCE expression in CD4low pDC were 2-fold
higher than in resting CD4high pDC. We also assessed TRANCE
expression in TLR3 (polyI:C), TLR4 (LPS) and TLR9 (CpG B)-
activated spleen CD4+ and CD42 cDC subsets but did not
observed any significant upregulation of TRANCE mRNA as
compared to resting cells (data not shown).
The mRNA for TRANCE-receptor, also called RANK, was not
expressed by DC at resting state but was strongly upregulated after
maturation in cDC as we previously reported [17], and to a much
lesser extent in pDC (data not shown). However, unlike on cDC,
RANK protein was not detected on the surface of mature pDC
(data not shown). A very similar expression profile was observed
for the decoy receptor of TRANCE, OPG, yet with a higher
expression at resting state for CD4+ cDC (data not shown).
Rat pDC express membrane TRANCE protein
TRANCE protein expression on pDC was assessed using a
polyclonal Ab to mTRANCE, a fusion protein between murine
RANK and a human Fc fragment (RANK-Fc), or OPG-Fc. We
observe staining on CD4high pDC with all these reagents (Fig. 2A).
OPG-Fc gave the strongest signal but because OPG is known to
also bind to TNF-related apoptosis inducing ligand (TRAIL) [26]
and because pDC can express TRAIL under certain conditions
[27], we decided to use Rank-Fc in the following experiments. The
specificity of Rank-Fc staining was confirmed by blocking the
fusion protein with soluble TRANCE as shown in figure 2B. As a
positive control, we used, as we previously described [24], ConA-
activated lymph node T cells which exhibited surface TRANCE
expression after 24 h stimulation (Fig. 2C). Confirming the PCR
data, we observed constitutive TRANCE expression on resting
CD4high pDC but not on CD4+ or CD42 cDC (Fig. 3). This
expression was maintained after 24 h of stimulation by CpG
whereas it was not detected on TLR9 (Fig. 3) TLR3 or TLR4
(data not shown) activated CD4+ or CD42 spleen cDC.
It was important to confirm that TRANCE-expressing 85C7+
CD45R+ cells have indeed pDC features. Therefore we sorted
TRANCE+ and TRANCE2 85C7+ CD45R+ cells and (Fig. 4A)
compared E2-2 (a transcription factor required for pDC
differentiation and function [28]) expression in these cells as well
as IFNa expression after stimulation with type A CpG. As shown
in figure 4B, both TRANCE+ and TRANCE2 85C7+ CD45R+
cells similarly expressed high levels of E2-2 mRNA as compared to
spleen cDCs. In the absence of available rat IFNa specific Ab, we
assessed its expression by QPCR. As shown in figure 4C, we
observed a strong induction of IFNa mRNA expression upon
TLR9 triggering in both subsets, this induction being nevertheless
stronger in TRANCE2 as compared to TRANCE+ 85C7+ CD45+
cells. Taken together, these data confirm that TRANCE
expressing 85C7+ CD45R+ cells are pDC.
Because rat pDC express CD45R, a B cells marker, and because
mouse and human B cells were described to express TRANCE
after maturation [29,30], we investigate TRANCE expression on
resting and activated sorted rat B cells. In our hand, resting or
activated B cells did not express TRANCE protein (data not
shown). Previous studies have shown that TRANCE is constitu-
tively expressed on a subset of CD4+CD32 progenitor cells that
are involved in induction of lymphoid tissues [31]. Although we
could not completely exclude that such cells could contaminate
our pDC suspensions, the extremely low frequency of lymphoid
tissues inducer cells in adults lymphoid organs as compared to that
of pDC exclude such a contamination accounted for the
TRANCE expression we observed on pDC.
We also assessed TRANCE expression on various immune cell
subsets in rat spleen (CD4+ and CD8+ T cells, B cells, NK cells,
CD11b/c+ cells, cDC). Unlike pDC, all these cells stained negative
for TRANCE (Fig. 5A). When pDC were permeabilized, we could
actually detect higher expression of TRANCE (data not shown)
indicating strong intracellular expression. The difference between
intracellular and membrane expression could be due to the
production of the soluble form of TRANCE instead of the
membrane form or could also be due to the cleavage of the
membrane form by the metalloprotease TACE (ADAM17) which
is known to release the membrane form of TRANCE into a
soluble form [32]. Next we assessed TRANCE expression on pDC
from different immune compartments (lymph node, thymus, bone
marrow and blood) (Fig. 5B). In all organs analyzed, pDC were
found to express TRANCE yet at different levels. A significant
highest expression of TRANCE was found on pDC from
mesenteric lymph nodes (mean (n= 3) of MFIs (SD) for TRANCE
expression on pDC from: Blood: 92 (62); BM: 80 (26): MLN: 316
(168); Spleen:112 (9); Thymus: 55 (11)).
Rat pDC Express TRANCE
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Figure 1. TRANCE mRNA expression on DC and pDC subsets. A. The expression of TRANCE mRNA was assessed in total mRNA prepared from
FACS-sorted spleen cDCs and pDCs (n = 3) and from lymph node cells (n = 3) before and after activation with ConA. B. Gating strategy for sorting pDC
subsets. After positive selection of 85C7+ cell, cells were stained with anti-CD45R and anti-CD4 mAbs, then sorted as 85C7+CD45R+CD4high and CD4low
cells (dot plots, before FACS-sorting). Purity was routinely .99.5% for both population (Dot plots, after FACS-sorting). Sorted pDC subsets were also
stained with anti-Siglec-H Ab (histrograms, after FACS-sorting). C. The expression of TRANCE mRNA was assessed in CD4+ and CD42 subsets of pDCs
at resting state and after maturation in presence of either CpG A or B. The results are expressed as a ratio of TRANCE to HPRT mRNA expression and
represent the mean 6 SD of three independent experiments. *, p,0,05; **, p,0,01; ***, p,0.001.
doi:10.1371/journal.pone.0033713.g001
Rat pDC Express TRANCE
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Figure 2. Surface TRANCE protein detection. A. Freshly FACS sorted CD4high pDC were stained with a polyclonal antibody to TRANCE, OPG-Fc
or RANK-Fc. B. Resting and Con-A-activated lymph node cells were stained with RANK-Fc and used as a positive control. C. RANK-Fc was
preincubated with soluble TRANCE for 20 minutes at 4uC before staining pDC as in A.
doi:10.1371/journal.pone.0033713.g002
Figure 3. TRANCE protein expression on spleen DC subsets. Freshly isolated (upper histograms) or 24 h CpG B-stimulated (lower histrograms)
CD4+ cDCs, CD42 cDCs and CD4high pDC or were stained with RANK-Fc (bold histrogram) or control Ig (dotted histogram).
doi:10.1371/journal.pone.0033713.g003
Rat pDC Express TRANCE
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We compared the kinetics of TRANCE expression on purified
CD4high versus CD4low pDC (Fig. 6) following TLR9 stimulation.
As expected, TRANCE protein was expressed at very low levels on
resting CD4low pDC. Following activation by CpG, TRANCE
expression was maintained on CD4high pDC for at least 48 h
whereas its expression was strongly induced on CD4low pDC. It is
interesting to note that CD4low pDC are the predominant subset in
bone marrow and blood (data not shown).
We failed to detect TRANCE expression in spleen pDC in mice
either at the mRNA (Fig. S1) or the membrane or soluble protein
levels (data not shown). In human, analysis of public data from
gene array experiment (http://amazonia.transcriptome.eu/;
http://www.immgen.org/index_content.html), indicated that rest-
ing human pDC did not express TRANCE mRNA. This was
confirmed by RT-PCR analysis of blood DC subsets (data not
shown) TRANCE being highly conserved between species and
pDC also, it is surprising that TRANCE expression on pDC is
restricted to rat model. It could be due to evolutionary
modifications specific to rat phylogeny.
Soluble TRANCE protein production by pDC
In addition to its membrane bound form, TRANCE can also be
produced as a soluble protein. Using an available ELISA for
Figure 4. E2-2 and IFNa expression by TRANCE+ and 2 pDCs. A. Gating strategy for isolating TRANCE+ and 2 spleen pDC. After positive
selection of 85C7+ cells (left dot plot), cells were stained with CD45R mAb and Rank-Fc. TRANCE2 and TRANCE+ 85C7+CD45R+ cells were sorted on a
FACS Aria (middle dot plot). Purity was .98% for both population (right dot plots). B. E2-2 mRNA expression was assessed by Q-PCR in FACS sorted
TRANCE+ (TR+) and – (TR2) population as well as in splenic cDCs (n = 2). C. The expression of IFNa mRNA was assessed by Q-PCR in FACS-sorted
population (n = 3) as well as in 85C7+CD45R+ cells (total pDC), at resting state and after 6 h activation with CpG 2216 (5 mM). The results are expressed
as a ratio of IFNa to HPRT mRNA expression and represent the mean 6 SD of two or three independent experiments.
doi:10.1371/journal.pone.0033713.g004
Rat pDC Express TRANCE
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mouse TRANCE, we were able to detect rat TRANCE (Fig. 7). In
supernatants from ConA-stimulated lymph node T cells which
serve as positive control, we could detect an increased quantity of
soluble TRANCE from 6 h to 48 h of culture. We did not detect
significant levels of TRANCE in the supernatant of either CD4+ or
CD42 cDC. After 24 h stimulation with TLR 9 ligands, CD4high
pDC produce 150 pg/mL612 pg/mL of soluble TRANCE.
Consistent with their higher expression of TRANCE mRNA after
stimulation, CD4low pDC produce 2-fold more soluble TRANCE
when they were cultured 24 h with a TLR9 ligand. Interestingly,
these levels were higher than that produced by activated T cells.
We could not detect soluble TRANCE in the supernatants of
purified rat B cells cultured 24 h and 48 h with CpG A or B or
LPS nor in the supernatants of CpG of LPS-activated cDCs
subsets (data not shown).
Lack of pDC-mediated osteoclastogenesis
We finally sought to assess whether rat pDC could induce
osteoclastogenesis in vitro. Indeed, osteoclastogenesis mediated by
TRANCE expressing T cells is already described [33]. We found
that CD4high and CD4low pDC, after a short-term stimulation or
24 h with CpG 2006, were not able to promote osteoclastogenesis
(data not shown) and surprisingly rather inhibit soluble TRANCE-
mediated in vitro osteoclastogenesis (Fig. 8). Fixed cells also failed
to induce osteoclastogenesis suggesting that soluble factors
produced by pDC such as IFNa [34] which are known to inhibit
osteoclastogenesis were not involved. Although the amount of
soluble TRANCE produced by pDC is almost 1,000-fold lower
than the quantity of exogenous TRANCE necessary to induce
osteoclasts formation in vitro, activated T cells were shown to
induce osteoclastogenesis in the same conditions. Therefore, these
negatitve in vitro data do not exclude a potential role of pDC in
regulating bone homeostasis in vivo and, moreover, pDC might
cooperate with other cells such as osteoblastic stromal cells,
osteoblasts or bone marrow stromal cells which, in response to IL-
6 produced by activated pDC, can produce soluble TRANCE
[35].
Conclusion
In conclusion, our data indicate that rat CD4high pDC
constitutively expressed TRANCE both at the mRNA and the
protein levels. Although TRANCE is expressed at very low levels
on resting CD4low pDC, it is strongly upregulated after TLR-
mediated activation. Whether CD4low and CD4high pDC
represent different developmental stage or different subsets of
pDC remains to be determined. However, the fact that CD4low
pDC were mainly found in bone marrow and blood while CD4high
pDC were dominant in lymphoid organs suggest that CD4low pDC
Figure 5. TRANCE expression on pDC in various lymphoid organs. A. Freshly prepared spleen cells were stained with various antibodies to
identify CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), B cells (CD45R+OX33+), NK cells (NKR-P1A highCD32), CD11b/c+ cells, cDC (CD103+), pDC
(85C7+ CD4+) together with RANK-Fc (bold histogram) or the secondary Ab alone (dotted histogram). B. Cell suspensions from various lymphoid
organs were stained with 85C7 and CD4 antibodies to identify CD4high pDC and RANK-Fc (bold histogram) or the secondary Ab alone (dotted
histogram). Similar results were obtained in 3 independent experiments for each panel.
doi:10.1371/journal.pone.0033713.g005
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Figure 7. Soluble TRANCE production by pDCs. Freshly sorted splenic pDC (n = 4) and cDC (n = 3) were stimulated in complete RPMI with CpG B
or A (5 mM). Lymph node cells were stimulated with ConA (5 mg/mL). Supernatants were collected at 6 and 24 h and soluble TRANCE was assessed by
ELISA (R&D systems). The detection threshold of the ELISA was 24 pg/mL. ***, p,0.001.
doi:10.1371/journal.pone.0033713.g007
Figure 6. Kinetics of TRANCE protein expression on activated pDCs. FACS sorted CD4high (upper panels) and CD4low (lower panels) pDC
were stimulated with CpG B and stained stained with RANK-Fc (bold lines) or the secondary Ab alone (thin lines) at 0 (resting), 6, 24 and 48 h after
stimulation. Similar results were obtained in 3 independent experiments.
doi:10.1371/journal.pone.0033713.g006
Rat pDC Express TRANCE
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could be the precursors of CD4high pDC. This is consistant with
the recent description of CD42 and CD4+ pDC subsets in mice
[11]. TRANCE was found to be expressed by rat pDC as a
membrane bound and a soluble protein, the levels of which were
similar of higher than that produced by activated T cells.
Intriguingly this specific phenotype of pDC appears to be rat-
specific as we so far did not find evidence of TRANCE expression
on murine or human pDC. The functional role of TRANCE on
pDC remains to be determined. Given the critical role of
TRANCE in osteoclastogenesis, pDC could play in vivo, such as
activated T cells, a role in regulating bone metabolism in rats,
although in vitro, we failed to demonstrate that pDC could induce
osteoclastogenesis. A recent report also indicate that Treg have an
important pro-metastatic function through their expression of
TRANCE in breast cancer [36]. Of note, pDC infiltration of
breast tumor was found to correlate with an adverse outcome [37].
Whether pDC can express TRANCE in tumor remains to be
determined. Recent studies indicate that pDC could enhance cDC
function through CD40L expression [38,39]. In the rat immune
system, pDC could therefore through their expression of
TRANCE act as survival and activating factor for cDC for
enhancing specific immune responses [17].
Materials and Methods
Animals
Lewis rats, from 8 to 12 week old were obtained from the
Centre d’Elevage Janvier (Le Genest St Isles, France). All animal
experiments were performed under specific pathogen-free condi-
tions in accordance with the European Union Guidelines. All
animal studies were conducted according to the guidelines of the
French Agriculture Ministry. The studies were approved by the
Veterinary Departmental Services committee (# E.44011).
Reagents
The phosphodiester oligonucleotide containing the CpG motif
(CpG ODN) 2006 (tcgtcgttttgtcgttttgtcgtt) and 2216 (ggGGGAC-
GATCGTCgggggg) were synthesized by Eurofins MWG Operon
(Ebersberg, Germany). Monensine, brefeldin A and Concanava-
line A were obtained from Sigma-Aldrich (Saint-louis, MI).
Antibodies
The Rank-human Fc fusion molecule and the mTRANCE-
human CD8 fusion molecule were kindly provided by Yongwon
Choi (University of Pennsylvania, Philadelphia). CD4-Phycoer-
ythrine (PE)-Cy7, and CD45R-PE monoclonal antibody were
purchased from BD Biosciences (Le Pont de Claix, France). R7/3
(TCRab), OX8 (CD8), OX12 (Igk), OX33 (CD45RA), OX35
(CD4), OX42 (CD11b/c) hybridomas were obtained from the
European Collection of Cell Culture, and mAb were purified from
supernatants followed or not by coupling to Alexa Fluor 647 and
Alexa Fluor 488 (Invitrogen, Cergy Pontoise, France). The anti-
human Fc-FITC monoclonal antibody was purchased from
Jackson ImmunoResearch Laboratories Europe Ltd (Suffolk, UK).
Dendritic cells sorting
Conventional DC. CD4+ and CD42 cDC were isolated as
previously described [22]. Briefly, after digestion in collagenase D
(Roche Diagnostics, Meylan, France), low density spleen cells were
selected on a 14.5% Nycodenz (Nycomed, Oslo, Norway)
gradient. CD103+ cells were then selected using OX62-MACS
microbeads (Miltenyi Biotec, Paris, France) and stained with
CD103-Alexa Fluor 647 (Clone OX62) and CD4-PE mAbs.
CD103+ CD4+ and CD103+ CD42 cells were sorted using a
FACS Aria (BD Biosciences).
Plasmacytoid DC. Spleens were perfused with 2 mg/mL
collagenase D in RPMI 1640/1% FCS, chopped into small pieces
and incubated 25 min at 37uC. EDTA (10 mM) was added, and
the cell suspension was pipetted up and down for 5 min and
filtered on 100 mm. Cells were washed in PBS/0.5 mM EDTA/
2% FCS and mononuclear cells were isolated by centrifugation
over Ficoll-Plaque Plus (Amersham, Les Ulis, France). T and
partial B cell depletion was then performed by incubating cells
with CD8 (OX8), Igk (OX12), CD45RA (OX33), CD11b/c
(OX42), TCRab (R7.3) and TCRcd (V65) mAbs followed by anti-
mouse IgG-coated magnetic beads (Invitrogen). After staining with
biotinylated 85C7 mAb, cells were incubated with anti-biotin
conjugated MACS Microbeads following the manufacturer’s
intructions (Miltenyi Biotec). Positive selection was performed on
AutoMACS Separator (Miltenyi Biotec). Cells were then stained
with. 85C7+ CD45R+ CD4high and 85C7+ CD45R+ CD4low cells
were sorted on a FACS Aria (BD biosciences). Purity was routinely
.99%. When indicated, 85C7+ enriched cells were stained with
Streptavidine-PerCp Cy5.5, CD45R-PE (HIS24) mAbs and
RANK-Fc followed by FITC anti-human Fc Ab and sorted on a
FACS Aria.
Flow cytometry analysis
Cells were stained using PBS diluted Ab and washed with PBS/
0.2% FCS/0.01% Azide. Intracellular staining was realised using
the Fixation/Permeabilization Diluent (eBiosciences, San Diego,
CA) and the Permeabilization Buffer (106) (eBiosciences)
Figure 8. pDCs inhibits in vitro osteoclastogenesis. Bone marrow cells were differentiated in osteoclast and stained for their expression of
tartrate-resistant acid phosphatase (TRAP) (Leukocyte Acid Phosphatase Assay kit; Sigma). Soluble TRANCE was used 100 ng/mL as a positive control
for the induction of osteoclasts. When indicated, 26105 FACS sorted CD4high pDC were added to bone marrow cells at day 0 in addition to TRANCE.
pDCs were shown to inhibit TRANCE-mediated osteoclastogenesis in these conditions. These results are representative of 5 independent
experiments.
doi:10.1371/journal.pone.0033713.g008
Rat pDC Express TRANCE
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according to manufacturer’s instructions. Cells were then acquired
on a BD FACS LSRII (BD biosiences) and results were analyzed
using FlowJo software (Treestar, Ashland, OR)).
Real-Time Quantitative PCR
Total RNA from 26105 to 26106 resting or stimulated DC
subsets and lymph node cells was extracted using Trizol (Life
Technologies, Paisley, U.K.) and synthesized to cDNA. Real-time
quantitative PCR was performed with this cDNA using an Applied
Biosystems GenAmp 7700 Sequence Detection System. TaqMan
probes sequences used were: rTRANCE forward: CAGAATAT-
CAGAAGACAGCACGC; rTRANCE reverse: AGCCAC-
GAACCTTCCATCAT, resulting in a 225-bp PCR product in
rat model; and rHPRT forward: CCTTGGTCAAGCAGTA-
CAGCC; rHPRT reverse: TTCGCTGATGACACAAACATGA,
resulting in a 188-bp PCR product; mTRANCE forward:
CACACCTCACCATCAATGCTG; mTRANCE reverse:
AGAATTGCCCGACCAGTTTT resulting in a 307-bp PCR
product in mouse model; Total cDNA was amplified in a 25 mL
reaction PCR mix constituted of 10 mL of diluted cDNA, 12.5 mL
of TaqMan SybrGreen 26PCR Master Mix (Applied Biosystems,
Applera, Courtaboeuf, France) containing AmpliTaq Gold DNA
polymerase, dNTPs with dUTP and optimized buffer components,
and 0.8 mL of 206TaqMan probes. The reaction started with a
step of 2 min at 50uC and 10 min at 95uC followed by 40 cycles
consisting of 15 s at 95uC and 1 min at 60uC. Relative expression
was calculated using the 222DDCt method and expressed in
arbitrary units.
ELISA test
The amount of soluble TRANCE in the supernatants of DC
and lymph node cell cultures was measured using a mouse ELISA
kit (R&D Systems, Minneapolis, MN) according to the manufac-
turer’s instructions.
Osteoclast Differentiation Assay
Tibias and femurs were harvested under sterile condition and
washed with 75% alcohol. Bone Marrow (BM) was washed out
with PBS/0.5 mM EDTA/2% FCS using disposable syringes.
Cells were washed after red blood cell lysis, and suspended at 107
cells/mL in MEM Alpha Medium (GIBCO, USA)/10% FCS in 6-
well culture plates. During the 16 first hours of culture at 37uC,
BM cells are in the presence of 5 ng/mL of Macrophage Colony
Stimulating Factor (M-CSF) (Peprotech, Rocky Hill, NJ). After this
step, non-adherent cells are washed and cultured for 3 more days
with 30 ng/mL M-CSF and 1 ng/mL transforming growth factor
(TGF-b)(R&D systems). Then adherent cells, after washing, are
cultured in the presence of 30 ng/mL M-CSF and various
conditions: With or without soluble TRANCE at 100 ng/mL, in
the presence or not of pDC, resting or stimulated 3 hours with
5 mM CpG ODN 2006 and in the presence or not of lymph node
cells stimulated 24 h with 5 mg/mL Concanavaline A. After three
days, presence or absence of osteoclasts is revealed by tartrate-
resistant acid phosphatase (TRAP) staining (Leukocyte Acid
Phosphatase Assay kit; Sigma) [26].
Statistical analysis
Statistical significance was evaluated using a two-way ANOVA
test and a Bonferoni Post-test. p#0.05 were considered significant.
Supporting Information
Figure S1 Spleen murine pDC do not express TRANCE
mRNA. Spleen CD8+ and CD82 cDC subset, total pDC
(mpDCA1+ B220+ cells) as well as CD4+ and CD42 pDC were
FACS sorted. TRANCE mRNA expression was assessed by Q-
PCR in resting cells or after 6 h stimulation with type B CpG for
CD4+ and CD42 pDC subsets. As positive control, we used lymph
node cells stimulated by Concanavalin A for 6 h ou 24 h.
Histograms represent the mean+SD of TRANCE mRNA
expression (arbitrary units) of 3 independent experiments.
(TIFF)
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